About this product
Much of the research around CBDV has centered around its effect on seizures. GW Pharmaceuticals, which developed the first FDA-approved CBD drug called Epidiolex, is actively developing a CBDV-based drug known as GPW42006 to reduce or prevent epileptic and other forms of seizures. Their research has shown that CBDV affects the neurochemical pathway of the capsaicin receptors involved in both the onset as well as the progression of several types of epilepsy. GW reports that CBDV has shown anti-epileptic results “across a range of in vitro and in vivo models of epilepsy.”
You may also like
You recently viewed
"(1) Marijuana has intoxicating effects and may be habit forming and addictive."; (2) "Marijuana impairs concentration, coordination, and judgment. Do not operate a vehicle or machinery under its influence."; (3) "There are health risks associated with consumption of marijuana."; (4) "For use only by adults twenty-one and older. Keep out of the reach of children."; (5) "Marijuana should not be used by women who are pregnant or breast feeding."